| Secondary |
| Renal Transplant |
46.2% |
| Nephrotic Syndrome |
23.2% |
| Rheumatoid Arthritis |
5.7% |
| Immunosuppression |
4.6% |
| Product Used For Unknown Indication |
3.6% |
| Systemic Lupus Erythematosus |
3.6% |
| Immunosuppressant Drug Therapy |
3.0% |
| Castleman's Disease |
1.6% |
| Prophylaxis |
1.4% |
| Collagen-vascular Disease |
1.1% |
| Iga Nephropathy |
1.1% |
| Pemphigoid |
0.8% |
| Arthralgia |
0.5% |
| Arthritis |
0.5% |
| Hypertension |
0.5% |
| Hyperuricaemia |
0.5% |
| Myocardial Infarction |
0.5% |
| Pancreatic Carcinoma |
0.5% |
| Rhinitis Allergic |
0.5% |
| Drug Use For Unknown Indication |
0.3% |
|
| Urine Analysis Abnormal |
23.2% |
| Nephrotic Syndrome |
17.4% |
| Toxicity To Various Agents |
10.1% |
| Renal Impairment |
7.2% |
| Thrombotic Microangiopathy |
7.2% |
| Atrial Fibrillation |
4.3% |
| Renal Graft Loss |
4.3% |
| Haemorrhage Subcutaneous |
2.9% |
| Protein Urine Present |
2.9% |
| Respiratory Failure |
2.9% |
| Staphylococcal Infection |
2.9% |
| Vasculitis |
2.9% |
| Arthralgia |
1.4% |
| Cardiac Failure |
1.4% |
| Colitis Ischaemic |
1.4% |
| Colon Cancer Metastatic |
1.4% |
| Computerised Tomogram Abdomen Abnormal |
1.4% |
| Electrolyte Imbalance |
1.4% |
| Erythema Infectiosum |
1.4% |
| Fatigue |
1.4% |
|
| Concomitant |
| Rheumatoid Arthritis |
35.6% |
| Renal Transplant |
16.5% |
| Nephrotic Syndrome |
7.6% |
| Drug Use For Unknown Indication |
6.8% |
| Prophylaxis |
4.8% |
| Product Used For Unknown Indication |
3.8% |
| Immunosuppression |
3.1% |
| Immunosuppressant Drug Therapy |
2.9% |
| Focal Segmental Glomerulosclerosis |
2.8% |
| Hypertension |
2.8% |
| Systemic Lupus Erythematosus |
2.3% |
| Lupus Nephritis |
1.7% |
| Antibiotic Prophylaxis |
1.6% |
| Prophylaxis Against Transplant Rejection |
1.6% |
| Osteoporosis |
1.3% |
| Glomerulonephritis Minimal Lesion |
1.1% |
| Hyperuricaemia |
1.0% |
| Rheumatoid Vasculitis |
1.0% |
| Infection Prophylaxis |
0.8% |
| Osteoporosis Prophylaxis |
0.8% |
|
| Renal Impairment |
8.6% |
| Pyrexia |
7.8% |
| Renal Failure Acute |
7.0% |
| Pneumonia |
6.3% |
| Pulmonary Embolism |
6.3% |
| Rheumatoid Arthritis |
6.3% |
| Weight Increased |
6.3% |
| Nephrotic Syndrome |
5.5% |
| Systemic Lupus Erythematosus |
5.5% |
| Thrombocytopenia |
5.5% |
| Renal Tubular Necrosis |
4.7% |
| Interstitial Lung Disease |
3.9% |
| Kidney Transplant Rejection |
3.9% |
| White Blood Cell Count Increased |
3.9% |
| Blood Alkaline Phosphatase Increased |
3.1% |
| Depression |
3.1% |
| Gait Disturbance |
3.1% |
| Lupus Nephritis |
3.1% |
| Osteonecrosis |
3.1% |
| Proteinuria |
3.1% |
|
| Interacting |
| Rheumatoid Arthritis |
30.0% |
| Drug Use For Unknown Indication |
20.8% |
| Hypertension |
8.3% |
| Gastritis Prophylaxis |
7.5% |
| Liver Disorder |
7.5% |
| Osteoporosis |
7.5% |
| Prophylaxis |
7.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
7.5% |
| Drug Therapy |
1.7% |
| Epilepsy |
0.8% |
| Pemphigoid |
0.8% |
|
| Pyrexia |
90.0% |
| Pemphigoid |
10.0% |
|
